Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7866817rdf:typepubmed:Citationlld:pubmed
pubmed-article:7866817lifeskim:mentionsumls-concept:C0004763lld:lifeskim
pubmed-article:7866817lifeskim:mentionsumls-concept:C0079419lld:lifeskim
pubmed-article:7866817lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:7866817lifeskim:mentionsumls-concept:C1522609lld:lifeskim
pubmed-article:7866817lifeskim:mentionsumls-concept:C1554112lld:lifeskim
pubmed-article:7866817pubmed:issue1lld:pubmed
pubmed-article:7866817pubmed:dateCreated1995-3-30lld:pubmed
pubmed-article:7866817pubmed:abstractTextDuring the last 30 years, the incidence of oesophageal adenocarcinoma has increased rapidly. Patients with Barrett's oesophagus have an increased risk of developing oesophageal adenocarcinoma and should be kept under surveillance. However, only a subset of Barrett's oesophagus patients will eventually develop malignancy and surveillance programs using endoscopy and histopathology cannot efficiently identify this subgroup. The study of additional prognostic factors is therefore of major importance and the p53 tumour suppressor gene has attracted much attention in this respect. Several investigators have found that p53 alteration is a frequent event in oesophageal adenocarcinomas and is associated with malignant transformation of Barrett's oesophagus. p53 appears to be a promising prognostic marker in Barrett's oesophagus and, as research progresses, possible clinical applications are emerging.lld:pubmed
pubmed-article:7866817pubmed:languageenglld:pubmed
pubmed-article:7866817pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7866817pubmed:citationSubsetIMlld:pubmed
pubmed-article:7866817pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7866817pubmed:statusMEDLINElld:pubmed
pubmed-article:7866817pubmed:monthJanlld:pubmed
pubmed-article:7866817pubmed:issn0954-691Xlld:pubmed
pubmed-article:7866817pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:7866817pubmed:authorpubmed-author:TilanusH WHWlld:pubmed
pubmed-article:7866817pubmed:authorpubmed-author:KrishnadathK...lld:pubmed
pubmed-article:7866817pubmed:issnTypePrintlld:pubmed
pubmed-article:7866817pubmed:volume7lld:pubmed
pubmed-article:7866817pubmed:ownerNLMlld:pubmed
pubmed-article:7866817pubmed:authorsCompleteYlld:pubmed
pubmed-article:7866817pubmed:pagination81-4lld:pubmed
pubmed-article:7866817pubmed:dateRevised2009-10-16lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:meshHeadingpubmed-meshheading:7866817-...lld:pubmed
pubmed-article:7866817pubmed:year1995lld:pubmed
pubmed-article:7866817pubmed:articleTitlePrognostic value of p53 in Barrett's oesophagus.lld:pubmed
pubmed-article:7866817pubmed:affiliationOesophageal Tumour Study Group, Dijkzigt Hospital, Erasmus University, Rotterdam, The Netherlands.lld:pubmed
pubmed-article:7866817pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7866817pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7866817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7866817lld:pubmed